You are here

Current Projects

 
  
 
Looking for a specific type of study? Finding the right fit is simple:
 1. Select your criteria below
 2. Press submit to view your results
 
  

The following projects are currently open and enrolling volunteers. These studies were evaluated and approved by the research team at Dr. Susan Love Research Foundation and members of our external Scientific Advisory Committee, comprised of researchers, clinicians, and advocates.

If you would like to learn about the studies we recruited for in the past, please click here.

  
Researcher: Mark Burkard, MD, PhD, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Broadcast date: May 10, 2018

Some people live for many years following a metastatic breast cancer diagnosis. To gain insight into why, researchers want to learn more about the medical history and health habits of women and men living with metastatic breast cancer. If you take part in this study, you will complete an online survey that will ask you questions about diet, exercise, health behaviors and medical care. Some participants who fill out the survey will also be invited to participate in an optional sub-study, which includes a medical record review, a blood or saliva sample, and tumor analysis. Findings from the survey and optional sub-study may help the research team discover how to help people live longer after a diagnosis of metastatic breast cancer.

Researcher: Seema Khan, MD, Northwestern University, Chicago, IL, Joseph Michael Guenther, MD, St. Elizabeth HealthCare, Edgewood, KY, Amy Degnim, MD, Mayo Clinic, Rochester, MN, Melissa Pilewskie, MD, Memorial Sloan Kettering Cancer Center, New York, NY, E. Shelley Hwang, MD, Duke University, Durham, NC, Stephen Grobmyer, MD, Cleveland Clinic, Cleveland, OH
Broadcast date: February 16, 2018

The purpose of this study is to compare the effects of a tamoxifen pill to tamoxifen (4-OHT) gel on breast cells in women with ER+ DCIS. This study will investigate what effects each treatment has on the DCIS and what side effects each treatment may cause. Prior studies show that the topical gel stays mainly in the breast itself with very little getting into the blood. The eventual goal is to provide women with DCIS with an alternative to oral tamoxifen treatment.

Researcher: Laura Esserman, MD, MBA, University of California, San Francisco, CA and her partners from the Athena Breast Health Network (a collaboration across the five University of California Medical Centers and Sanford Health)
Broadcast date: February 16, 2018

Women receive mixed messages about what type of breast cancer screening they should have and how often they should have mammograms. The WISDOM Study compares the routine, annual mammogram schedule to a personalized screening schedule based on a woman’s individual risk factors. The goal of the study is to determine the best way to use mammograms to improve breast cancer screening while reducing the number of call backs, false alarms, and biopsies for women who do not have breast cancer.

Researcher: Tonia Poteat, PhD, and Lorraine T. Dean, ScD of Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Broadcast date: January 12, 2018

The purpose of this study is to learn about the best ways to improve access to breast cancer care and treatment for members of the Black LGBQ-SGL community. The research team will enroll up to 30 participants for an in-depth phone interview about identities and healthcare experiences.  

Researcher: N. Lynn Henry, MD, PhD; Anna Beck, MD; Adam Cohen, MD; Saundra Buys, MD; John Ward, MD; Hung Khong, MD; Elizabeth Prystas, MD
Broadcast date: October 3, 2017

The purpose of this study is to better understand why some breast cancer survivors who have chronic pain and are treated with duloxetine will have their level of pain improve, while others will not. Women with breast cancer who have chronic pain will be asked to enroll. Participants will be treated with duloxetine for 7 weeks in order to determine how the medication affects both their level of pain and their sensitivity to pain. The research team hopes to understand more about why breast cancer survivors develop pain after their diagnosis and treatment, and why some people respond better to this type of treatment. The research team needs 56 women to participate in this study.  

Researcher: Alexandra Zimmer, M.D., at the National Cancer Institute, Bethesda, MD
Broadcast date: September 19, 2017

The purpose of this study is to investigate whether using Temodar and Kadcyla together decreases the chance of patients with HER2+ metastatic breast cancer developing new brain metastases. Approximately 18 participants will take part in this study. Participants enrolled in this trial may be eligible to receive compensation for their travel expenses.

Researcher: Carolyn Westhoff, MD, Columbia University, New York, NY
Broadcast date: August 9, 2017

The purpose of this study is to learn how two different medications affect the breast: an estrogen-free selective progesterone-receptor modulator called UPA vs. a low-dose oral contraceptive pill. This is a randomized, phase I clinical trial. Participants have a 50% chance of receiving the UPA pill, and 50% chance of receiving the low-dose oral contraceptive.

Researcher: Thomas Mack, MD, MPH, University of Southern California, Los Angeles
Broadcast date: July 12, 2017

This study aims to identify non-genetic factors that cause only one twin in a pair to get breast cancer. This information could help researchers identify ways to help prevent breast cancer from occurring.

Researcher: David Spiegel, MD, Amit Etkin, MD, PhD, James Gross, PhD, and Allison Kurian, MD, MSc, Stanford University School of Medicine. The study is funded by the National Cancer Institute.
Broadcast date: June 7, 2017

The goal of this study is to better understand what women are thinking about and feeling as they decide on their cancer treatments. The results of this study may help researchers develop new interventions that may better assist women newly diagnosed with breast cancer with their treatment decisions.

Researcher: Patricia A. Ganz, MD, Julienne Bower, PhD, and Catherine Crespi, PhD at University of California: Los Angeles; Ann Partridge, MD, MPH and Hadine Jaffe, MD, MSc at Dana-Farber Cancer Institute; and Antonio Wolff, MD, Katherine Smith, PhD, and Elissa Bantug, MHS at Johns Hopkins University
Broadcast date: May 3, 2017

The purpose of this study is to see how well two different types of group programs—mindfulness-meditation classes and survivorship education classes—meet the needs of young survivors. Up to 360 women will take part in this study. Three institutions are collaborating on this project: University of California, Los Angeles, Dana-Farber Cancer Institute, and Johns Hopkins University

Pages